Symbiotec Pharmalab shares jump 6% as subsidiary secures distribution rights for injectable product in US

Pharmaceutical firm Symbiotec Pharmalab shares surged around 6% during the trading session on Thursday, October 1, as investors reacted to the company’s subsidiary securing exclusive rights to commercialise and distribute two Dual Chamber Vial-based injectable products in the United States.

NSE filings showed that Symbiotec Pharmalab’s wholly-owned subsidiary Knovea Pharmaceutical secured exclusive rights to commercialise and distribute two Dual Chamber Vial (DCV) - based injectable products in the United States.

NSE data showed that Symbiotec Pharmalab shares surged 5.8% to hit an intraday high of ₹1,246 apiece on Thursday’s market, in comparison to ₹1,176.75 apiece at the previous equity market close.

As of the afternoon market hours, trading volumes surged past 3.6 million equity shares on NSE and BSE combined, with the company’s stock trading 1% higher at around ₹1,189.30 apiece on October 1.

The company’s stock reacted during Thursday’s market as the firm filed its distribution rights update after market hours on Wednesday, September 30, 2026.

$288 million potential market

NSE filings showed that Symbiotec expects the two injectable products to address a market of approximately $288 million in the United States.

As per the details of the deal, Knovea will lead development, regulatory submissions, manufacturing and supply, while the partner drives commercialisation and distribution across the United States.

The company aims for the collaboration to be structured to deliver milestone payments through development, regulatory approval and commercial launch, alongside profit-sharing from launch onwards.

“Our sustained investment in building DCV capabilities end-to-end — from product development and regulatory science to commercial-scale sterile manufacturing — is now paying off, with a leading global pharmaceutical company as our exclusive U.S. partner,” said Anil Satwani, Managing Director of Symbiotec Pharmalab.

How have Symbiotec Pharma shares performed?

NSE data showed that Symbiotec Pharmalab shares have gained over 10% in the last one-month period, after the company’s shares were listed on the National Stock Exchange (NSE) on September 1, 2026.

The exchange data also showed that the company's shares have risen more than 18% in the last one-week period.

Since the company’s listing on the Indian stock market, Symbiotec Pharmalab shares have delivered more than 26% returns to investors as of Thursday’s market high, in comparison to the IPO issue price of ₹988 per share.

The company’s market capitalisation (m-cap) was at ₹7,698 crore as of the stock market session on Thursday, October 1, 2026.